Trevena Inc., of Chesterbrook, Pa., said it entered securities purchase agreements with two health care-focused institutional investors, to sell 10 million shares of its common stock at $1 each in a registered direct offering for gross proceeds of $10 million. It intends to use the net proceeds for the development of its lead product candidate, oliceridine, a G-protein biased mu-opioid receptor agonist, for the management of moderate to severe acute pain, and for other general corporate purposes.